Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Improved Child Nutrition and Development Through Social Transfers (TENDER)

28 avril 2026 mis à jour par: Jordyn Wallenborn, Swiss Tropical & Public Health Institute

Taabo Enhanced Nutrition and Development Through Economic Rewards

The goal of this clinical trial is to learn if a conditional social transfer works to improve rates of complementary breastfeeding. It will also learn about the impacts of social transfers on maternal and child health and development. The main questions it aims to answer are:

  • Does the social transfer increase complementary breastfeeding rates at 24-months postpartum?
  • Does the social transfer increase complementary breastfeeding duration?
  • Does the social transfer impact child health and development?
  • Does the social transfer impact maternal physical and mental health?

Researchers will compare a conditional social transfer to a control group that only receives education about breastfeeding recommendations to see if a conditional social transfers works to increase complementary breastfeeding.

Participants will:

Receive a pamphlet explaining the current recommendations of breastfeeding Receive instructions that if they meet the recommendation to breastfeed until 24-months postpartum they receive a social transfer or receive no additional information Complete home visits at 12- and 24-months postpartum Complete detailed questionnaire

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

1040

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Côte d’Ivoire
      • Taabo, Côte d’Ivoire
        • Taabo Health and Demographic Surveillance
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. Are enrolled in the Taabo multigenerational birth cohort (MGC)
  2. Completed the postpartum interview of the Taabo MGC
  3. Have a child who is within two weeks of their 12-month birthday,
  4. are breastfeeding at time of recruitment,
  5. live in the Taabo HDSS, Côte d'Ivoire
  6. have no illnesses that contraindicates breastfeeding,
  7. had a healthy singleton infant with a birth weight of at least 2500 grams, and
  8. agree to participate and sign an informed consent; if underage (12-17 years), a legal representative will also have to agree to sign the informed consent

Exclusion Criteria:

  1. Plans to move permanently outside study area
  2. Has a medical, intellectual or psychological disability
  3. Contraindication for breastfeeding
  4. Children born with < 2500 grams

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Social Transfer
A social transfer is provided at the 24-month visit, conditional on the mother still breastfeeding at the time of the visit. They also receive education about current breastfeeding recommendations.
Autre: Social Transfer
A social transfer will be given conditioned upon breastfeeding at 24-months postpartum.
Aucune intervention: Control
No intervention is provided besides education on current breastfeeding recommendations.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Prevalence of Complementary Breastfeeding
Délai: from 12 to 24 months postpartum
Prevalence of complementary breastfeeding at 24 months postpartum.
from 12 to 24 months postpartum
Complementary Breastfeeding Duration
Délai: from 12 to 24 months postpartum
Duration of complementary breastfeeding in weeks.
from 12 to 24 months postpartum

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Weight-for-Age z-score
Délai: 12 months; 24 months
Infants will be weighed in kilograms by a mobile weighing scale. Measurements will be analyzed as age standardized z-scores.
12 months; 24 months
Child Health Outcomes
Délai: 12 months; 24 months
We will assess the child's health outcomes by using a questionnaire administered to the caregiver. The questionnaire will ask a range of yes or no questions about child diarrhea, respiratory illness, fever, and child antibiotic use.
12 months; 24 months
Percent weight loss
Délai: 12 months; 24 months;
Percent weight loss will use body weight (kg) and pregnancy weight of the mother controlling for time of measurement. Percent weight loss will be calculated as ((current weight - pregnancy weight) / pregnancy weight) × 100.
12 months; 24 months;
Mother and Child Hemoglobin Levels
Délai: 12 months; 24 months
We will assess the mother and child anemia levels. The HemoCue Hb 301 will be used to give an instant measurement of the Haemoglobin (Hb) level of the patient. Capillary blood will be collected through a finger prick. Blood samples drawn for the haemoglobin assessment will be discarded after the test. Iron levels will be analyzed as a continuous outcome.
12 months; 24 months
Maternal Depression
Délai: 12 months; 24 months
Maternal postpartum depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9); categorized as a binary: no depression (score <10) or depression present (score ≥10).
12 months; 24 months
Height-for-age z-score
Délai: 12 months; 24 months
Height will be measured in centimeters by using a Height Measuring Device, stadiometer, 20-205cm. All measurements will be analyzed as age standardized z-scores
12 months; 24 months
Mid-upper arm circumference (MUAC)
Délai: 12 months; 24 months
Infants will be measured for mid-upper arm circumference (MUAC) using non-stretchable measuring tape. All measurements will be analyzed as age standardized z-scores.
12 months; 24 months
Mother and Child Anemia
Délai: 12 months; 24 months
The HemoCue Hb 301 will be used to give an instant measurement of the Haemoglobin (Hb) level of the patient. Capillary blood will be collected through a finger prick. Blood samples drawn for the haemoglobin assessment will be discarded after the test. Hemoglobin levels (gm/dL) will be used to categorize mothers and children into a binary variable: anemic or not anemic.
12 months; 24 months
Maternal weight change
Délai: 12 months; 24 months;

Weight weight change will use body weight (kg) and pregnancy weight of the mother controlling for time of measurement. Maternal weight change will be calculated as the difference between postpartum weight and pregnancy weight. Because pregnancy weight varies by gestational age, analyses will control for gestational age at pregnancy weight measurement and time postpartum at outcome measurement.

Categorized as: no weight loss (0 kg); moderate weight loss (<0 to >-5 kg); high weight loss (≥-5 kg); moderate weight gain (>0 to <5 kg); high weight gain (≥5 kg).
12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg)
Délai: 12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg) from baseline of the mothers will be categorized as low, normal, or high according to standard clinical thresholds.
12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg)
Délai: 12 months; 24 months;
Change in systolic and diastolic blood pressure (mmHg) from baseline of the mothers will be analyzed as a continuous measure.
12 months; 24 months;
Caregiver Reported Early Development Instruments (CREDI) cognitive z-score
Délai: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI language z-score
Délai: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI motor z-score
Délai: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
CREDI social-emotional z-score
Délai: 12 months; 24 months
The CREDI long-form will be administered. Raw item data will be converted to norm-referenced z-scores using the CREDI scoring procedure.
12 months; 24 months
Maternal Anxiety
Délai: 12 months; 24 months
Maternal postpartum anziety will be assessed using the the GAD-7 (Generalized Anxiety Disorder-7); a seven-item self-report questionnaire designed to measure the severity of anxiety; categorized as: Minimal Anxiety: score 0-4; Mild Anxiety: score 5-9; Moderate Anxiety: score 10-14; Severe Anxiety: score 15-21
12 months; 24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Swiss Tropical & Public Health Institute

Collaborateurs

Centre Suisse de Recherches Scientifique en Côte d'Ivoire

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juin 2026

Achèvement primaire (Estimé)

28 février 2028

Achèvement de l'étude (Estimé)

28 février 2028

Dates d'inscription aux études

Première soumission

15 avril 2026

Première soumission répondant aux critères de contrôle qualité

28 avril 2026

Première publication (Réel)

6 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 avril 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 2025-50

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner